Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (MXCT) pioneers advanced cell engineering through its proprietary Flow Electroporation technology, enabling breakthroughs in gene therapy and biopharmaceutical development. This dedicated news hub provides investors and industry professionals with essential updates on MXCT’s strategic initiatives, financial performance, and scientific advancements.
Access timely press releases covering regulatory milestones, partnership announcements, and technology innovations. Our curated collection includes earnings reports, clinical trial updates, and analyses of MXCT’s role in advancing next-generation cell therapies. The platform serves as a critical resource for tracking the company’s impact on precision medicine and scalable therapeutic manufacturing.
Discover updates about MXCT’s ExPERT platform deployments, licensing agreements with biotech innovators, and expansions in global research collaborations. Content is organized for quick scanning while maintaining technical accuracy, ensuring relevance for both casual observers and specialized analysts.
Bookmark this page for streamlined access to verified MXCT developments. Combine our news feed with Stock Titan’s financial tools to monitor how MaxCyte’s cell engineering leadership translates into long-term market positioning.
MaxCyte (Nasdaq: MXCT) announced that Chief Financial Officer Douglas Swirsky will transition from his CFO role in the first half of 2026. Mr. Swirsky will remain CFO until a successor is appointed, will support a structured successor search, and will continue in an advisory capacity after the transition to support strategic initiatives and continuity.
The company and Mr. Swirsky say the planned, orderly handoff is not expected to affect operations, results, financial reporting cadence, or strategic priorities.
MaxCyte (NASDAQ: MXCT) reported third quarter 2025 results and reiterated full-year 2025 guidance on Nov 12, 2025. Total revenue was $6.8M in Q3 2025, down 16% year-over-year; core revenue was $6.4M, down 21% YoY. Gross profit was $5.2M (77% gross margin); non-GAAP adjusted gross margin was 81% versus 85% in Q3 2024. Q3 net loss was $12.4M; adjusted EBITDA loss improved to $10.0M from $13.0M. Installed instrument base rose to 830. Management reiterated 2025 guidance: core revenue flat to -10% and ~$5M SPL program revenue; expected year-end cash of $152M–$155M.
MaxCyte (NASDAQ: MXCT) reported preliminary third-quarter 2025 results and reiterated full-year 2025 revenue guidance on Nov 5, 2025. Q3 total revenue was $6.8M with core revenue $6.4M and SPL program-related revenue $0.4M. Gross margin was $5.2M (77%), with a non-GAAP adjusted gross margin of 81% excluding SPL and inventory reserves. Cash, cash equivalents and investments totaled $158.0M at September 30, 2025. The company is delaying the formal Q3 release and call to complete impairment testing of goodwill and long-lived assets; guidance sees year-end cash of $152M–$155M and SPL revenue ~$5M for 2025.
MaxCyte (NASDAQ: MXCT) will report third quarter 2025 financial results after the U.S. market close on Wednesday, November 5, 2025.
Company management will host an earnings conference call at 4:30 p.m. Eastern Time the same day. Investors must register online in advance to join the call, and a live and archived webcast will be available in the Events section of MaxCyte's investor website at https://investors.maxcyte.com/.
MaxCyte (Nasdaq: MXCT) signed a Strategic Platform License (SPL) with Moonlight Bio on Oct 6, 2025 to support development and scalable manufacturing of Moonlight's engineered T cell therapies for solid tumors. Moonlight gains non-exclusive research, clinical, and commercial rights to MaxCyte's Flow Electroporation® technology and ExPERT™ platform. MaxCyte will receive annual licensing fees and program-related revenue while Moonlight will use GMP-ready electroporation and regulatory support to build clinical manufacturing processes.
MaxCyte (NASDAQ:MXCT), a cell-engineering platform technology company, has announced a significant operational restructuring to optimize costs and accelerate profitability. The plan includes a 34% reduction in global workforce, expected to generate $13.6 million in annual savings.
The company reiterated its 2025 guidance, expecting core revenue to be flat to down 10% compared to 2024, with $5 million in SPL program-related revenue. MaxCyte projects to maintain at least $155 million in cash, cash equivalents, and investments by year-end.
MaxCyte (NASDAQ: MXCT) reported Q2 2025 financial results with mixed performance. The company's core business revenue reached $8.2 million, up 8% year-over-year, while total revenue decreased 18% to $8.5 million due to lower Strategic Platform License (SPL) Program-related revenue. The company added two new SPL clients, bringing the total to 31 agreements.
Key metrics show an installed base of 814 instruments and 42% of core revenue generated by SPL clients. The company updated its 2025 guidance, projecting core revenue to be flat to 10% down compared to 2024, with SPL Program-related revenue expected at approximately $5 million. MaxCyte anticipates ending 2025 with at least $155 million in cash and investments.
MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The non-exclusive license grants Adicet Bio research, clinical, and commercial rights to support their gamma delta T cell therapy gene edited programs.
Under the agreement, MaxCyte will receive platform licensing fees and program-related revenue. Adicet Bio will utilize MaxCyte's technology to enhance their proprietary manufacturing process for allogeneic gamma delta T cell therapies, aimed at treating cancer and autoimmune diseases.
The collaboration leverages MaxCyte's ExPERT™ platform, which provides high transfection efficiency, cell viability, and seamless scalability for complex cell engineering applications.
MaxCyte (NASDAQ:MXCT) has signed a Strategic Platform License Agreement with Anocca AB for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The agreement grants Anocca non-exclusive research, clinical, and commercial rights to support their TCR-T cell therapy development.
Under the agreement, MaxCyte will receive annual licensing fees and program-related revenue. The partnership aims to enhance Anocca's cell therapy manufacturing capabilities, particularly for their lead program targeting KRAS-driven advanced pancreatic cancer currently in clinical development. Anocca recently received GMP compliance certification and manufacturing license from Swedish regulators.
MaxCyte (NASDAQ: MXCT), a cell-engineering platform technology company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after the U.S. market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors must register online to participate, preferably a day in advance. A live and archived webcast will be available in the "Events" section of MaxCyte's investor relations website.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
